Intervention

daraxonrasib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting2

Common conditions14

Lead sponsors shown1

Clinical trials

2 shown

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537 · 2026-01-08

RECRUITING

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06

RECRUITING

Common conditions

NSCLC2 Advanced Solid Tumors1 Colorectal Cancer (CRC)1 CRC1 Lung Cancer (NSCLC)1 Non-Small Cell Lung Cancer1 Non-small Cell Lung Cancer (NSCLC)1 NSCLC (Advanced Non-small Cell Lung Cancer)1 NSCLC (Non-small Cell Lung Cancer)1 NSCLC (Non-small Cell Lung Carcinoma)1 Pancreatic Adenocarcinoma1 Pancreatic Cancer1 Pancreatic Ductal Adenocarcinoma (PDAC)1 PDAC1

Leading sponsors

Revolution Medicines, Inc. 2

Trial status mix

RECRUITING2

Phase mix

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.